ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2026, Vol. 35 ›› Issue (2): 190-194.DOI: 10.3969/j.issn.1006⁃298X.2026.02.018

• 病例报告 • 上一篇    下一篇

奥妥珠单抗治疗激素抵抗型微小病变肾病

  

  • 出版日期:2026-04-28 发布日期:2026-04-23

Obinutuzumab treatment for steroid⁃resistant minimal change disease

  • Online:2026-04-28 Published:2026-04-23

摘要: 17 岁男性患者临床表现为肾病综合征,肾活检病理电镜示肾小球足细胞足突广泛融合 (>90%), 胞质内见吞噬溶酶体,诊断为微小病变肾病 (MCD)。患者足量激素治疗 8 周后仍存在大量蛋白尿,符合激素抵抗型 MCD 诊断,完善检查示血清抗 nephrin 抗体阳性 (滴度 1∶30)。给予奥妥珠单抗 1g×2 次,尿蛋白迅速转阴,抗 nephrin 抗体 IgG 转阴;激素 5 个月减停,后续予以奥妥珠单抗 1g 治疗,随访期间患者肾病持续缓解。

关键词: 奥妥珠单抗, 微小病变肾病, 抗 nephrin 抗体

Abstract: A 17⁃year⁃old male patient presented with nephrotic syndrome.Renal biopsy revealed extensive foot process effacement (>90%) and cytoplasmic phagolysosomes in glomerular podocytes under the electron microscope,indicating a diagnosis of minimal change disease (MCD).Despite 8 weeks of full⁃dose corticosteroids,the patient exhibited persistent massive proteinuria,indicating steroid⁃resistant MCD.Serological testing revealed positive anti⁃nephrin antibody with a titer of 1∶30.After treatment with obinutuzumab (1g infusions for 2 doses),the patient achieved rapid remission of proteinuria and negative conversion of anti⁃nephrin IgG antibody.Corticosteroids were successfully tapered and discontinued over 5 months.Sustained remission of nephrotic syndrome has been achieved with obinutuzumab (1g) as maintenance therapy.